Tacrolimus is relatively safe and effective in reducing rejection and prolonging graft survival in subjects with high-risk keratoplasty.
Tacrolimus is relatively safe and effective in reducing rejection and prolonging graft survival in subjects with high-risk keratoplasty, according to a study published in the January issue of the British Journal of Ophthalmology.
Harminder Dua and colleagues from the University of Nottingham, UK enrolled 43 subjects undergoing high-risk corneal transplantation to receive systemic tacrolimus. Tacrolimus, a specific T cell inhibitor, was used at a mean daily dose of 2.5 mg for immunosupression and this was continued for between 18 and 24 months after the graft.
During a mean follow-up period of 33.7 months, 65% of subjects maintained clarity of graft, while eight subjects experienced rejection episodes, which led to graft failure in five.
It was concluded that tacrolimus offers a relatively safe and effective method of sustaining graft survival.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.